March 02, 2017
Concordia Pharmaceuticals Inc. on Thursday saw its $730,000 damages award against Method Pharmaceuticals LLC trebled to $2.2 million when a Virginia federal judge said an enhancement was warranted in the false advertising suit over Method's representation its irritable bowel syndrome medication was a valid generic substitute.
April 22, 2016
A Virginia federal jury determined Thursday that Method Pharmaceuticals LLC was liable to rival Concordia Pharmaceuticals Inc. for falsely advertising its irritable bowel syndrome medication as a generic substitute for a drug sold by Concordia, which the jury awarded approximately $730,000 in damages.